Cellumen to Develop Drug Toxicity Biomarkers for Mitsubishi Tanabe | GenomeWeb
NEW YORK (GenomeWeb News) – Cellumen said today that it will help Mitsubishi Tanabe Pharma to develop biomarker panels that could be used to help the company identify drug toxicity early in the drug development process.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.